Literature DB >> 22290840

Clomipramine and initial worsening in panic disorder: beyond the 'jitteriness syndrome'.

R T Ramos1, V Gentil, C Gorenstein.   

Abstract

The time course and the phenomenology of the initial response to clomipramine (10-20 mg/day) was investigated in 70 patients with panic disorder with or without agoraphobia. Nineteen (27.1%) patients reported worsening of their clinical state which, on average, began 28 h after the first dose and lasted for 5 days. Increase in the frequency and severity of panic attacks was the most frequent finding (14 patients), followed by psycho- stimulant (jitteriness; n=9), depressive (n=8) and tonic anxiety symptoms (n=7). This pattern of initial worsening is different from the 'jitteriness syndrome' described for other antidepressants. Its implications for the understanding of the pathophysiology of panic disorder are discussed.

Entities:  

Year:  1993        PMID: 22290840     DOI: 10.1177/026988119300700305

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  5 in total

1.  Inositol has behavioral effects with adaptation after chronic administration.

Authors:  H Cohen; M Kotler; Z Kaplan; M A Matar; O Kofman; R H Belmaker
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Acute escitalopram but not contextual conditioning exerts a stronger "anxiogenic" effect in rats with high baseline "anxiety" in the acoustic startle paradigm.

Authors:  Robert Pettersson; Jakob Näslund; Staffan Nilsson; Elias Eriksson; S Melker Hagsäter
Journal:  Psychopharmacology (Berl)       Date:  2014-11-25       Impact factor: 4.530

Review 3.  Pharmacological challenge studies with acute psychosocial stress.

Authors:  Kathryne Van Hedger; Anya K Bershad; Harriet de Wit
Journal:  Psychoneuroendocrinology       Date:  2017-08-22       Impact factor: 4.905

4.  Differences in Anxiety-Like Behavior within a Batch of Wistar Rats Are Associated with Differences in Serotonergic Transmission, Enhanced by Acute SRI Administration, and Abolished By Serotonin Depletion.

Authors:  Jakob Näslund; Erik Studer; Robert Pettersson; Melker Hagsäter; Staffan Nilsson; Hans Nissbrandt; Elias Eriksson
Journal:  Int J Neuropsychopharmacol       Date:  2015-02-25       Impact factor: 5.176

5.  Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.

Authors:  Mats B Humble; Kerstin Uvnäs-Moberg; Ingemar Engström; Susanne Bejerot
Journal:  BMC Psychiatry       Date:  2013-12-23       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.